Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

[1]  F. Paul,et al.  Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. , 2020, Brain : a journal of neurology.

[2]  G. Forloni,et al.  Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer’s mice , 2020, Cell Death & Differentiation.

[3]  L. Brundin,et al.  Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis—A Phase I Study , 2019, Journal of clinical medicine.

[4]  Jeffrey A. Cohen,et al.  Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation , 2019, Multiple sclerosis journal - experimental, translational and clinical.

[5]  C. Garlanda,et al.  Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure , 2019, Acta Neuropathologica.

[6]  M. Sormani,et al.  MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis , 2019, Trials.

[7]  J. Galipeau,et al.  Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. , 2018, Cell stem cell.

[8]  Jeffrey A. Cohen,et al.  Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis , 2018, Multiple sclerosis.

[9]  A. Diaspro,et al.  IFN‐&ggr; orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways , 2017, The Journal of allergy and clinical immunology.

[10]  J. M. Centanni,et al.  Biodistribution and Clearance of Human Mesenchymal Stem Cells by Quantitative Three-Dimensional Cryo-Imaging After Intravenous Infusion in a Rat Lung Injury Model , 2016, Stem cells translational medicine.

[11]  E. Andreu,et al.  Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis , 2014, PloS one.

[12]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[13]  Arnold I Caplan,et al.  Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models , 2012, Nature Neuroscience.

[14]  David H. Miller,et al.  Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study , 2012, The Lancet Neurology.

[15]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[16]  M. Freedman,et al.  Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases , 2011, The Lancet Neurology.

[17]  Jeff W M Bulte,et al.  Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. , 2010, Archives of neurology.

[18]  R. Mahfouz,et al.  Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study , 2010, Journal of Neuroimmunology.

[19]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[20]  H. Atkins,et al.  The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group , 2010, Multiple sclerosis.

[21]  L. Vergani,et al.  Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo , 2009, Journal of neurochemistry.

[22]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[23]  N. Shanks,et al.  Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.

[24]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[25]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[26]  Antonio Uccelli,et al.  Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis , 2007, Annals of neurology.

[27]  Ly Sun,et al.  Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus , 2007, Lupus.

[28]  M. Chopp,et al.  Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice , 2006, Journal of neuroscience research.

[29]  L. Lejeune,et al.  Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. , 2005, Blood.

[30]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[31]  S. Mckercher,et al.  Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. , 2000, Science.

[32]  F. Barkhof,et al.  Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results , 1999, Journal of neurology, neurosurgery, and psychiatry.

[33]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[34]  A. Friedenstein,et al.  HETEROTOPIC TRANSPLANTS OF BONE MARROW , 1968 .